Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
JCO Precision Oncology|April 23, 2025
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion CancerMarcia S Brose, C Benedikt Westphalen, Xiaoyun Pan, et al.
JAMA Otolaryngology-- Head & Neck Surgery|July 3, 2020
Targeted Oncogene Therapy Before Surgery in Pediatric Patients With Advanced Invasive Thyroid Cancer at Initial Presentation: Is It Time for a Paradigm Shift?Ken Kazahaya, Kara K Prickett, Vera A Paulson, et al.
The Journal of Clinical Endocrinology and Metabolism|December 11, 2008
Loss of Rap1GAP in papillary thyroid cancerAnoma Nellore, Karolina Paziana, Changqing Ma, et al.
Cancer|October 19, 2022
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trialMarcia S Brose, Bruce G Robinson, Steven I Sherman, et al.
The Lancet. Oncology|July 8, 2021
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialMarcia S Brose, Bruce Robinson, Steven I Sherman, et al.
Molecular Cancer Therapeutics|September 22, 2019
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION TrialJaume Capdevila, Ignacio Matos, Francesco M Mancuso, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
The Journal of Clinical Endocrinology and Metabolism|October 19, 2021
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid CancerMarcia S Brose, Yury Panaseykin, Bhavana Konda, et al.
BMC Cancer|March 6, 2019
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancerJanice M Mehnert, Andrea Varga, Marcia S Brose, et al.
Endocrine-Related Cancer|June 3, 2024
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapyMarcia S Brose, Jaume Capdevila, Rossella Elisei, et al.
Pageof 8